Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for Anaphylm™ at American College of Allergy Asthma and Immunology (ACAAI) Annual Meeting
November 10, 2023 08:00 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful...
Aquestive Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 06, 2023 16:37 ET
|
Aquestive Therapeutics, Inc.
Reiterates commencement of pivotal pharmacokinetic (PK) study for Anaphylm™ (epinephrine) Sublingual Film expected in fourth quarter 2023 with topline data targeted for first quarter 2024Completes...
Aquestive Therapeutics Completes $45 Million Debt Refinancing
November 02, 2023 08:00 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through...
Aquestive Therapeutics to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 6 and Host Conference Call on November 7 at 8:00 a.m. ET
October 31, 2023 08:00 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful...
Aquestive Therapeutics Provides Business Update
October 09, 2023 08:00 ET
|
Aquestive Therapeutics, Inc.
Receives positive feedback from FDA on pivotal study protocol for Anaphylm™ (epinephrine) Sublingual FilmReaffirms fourth quarter 2023 Anaphylm pivotal Phase 3 study start and first quarter 2024...
Aquestive Therapeutics Reaffirms Timeline and Pathway for Anaphylm™ (epinephrine) Sublingual Film
September 20, 2023 09:04 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care...
Aquestive Therapeutics Receives FDA Acceptance of New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film in Pediatric Patients and Assignment of Prescription Drug User Fee Act (PDUFA) Date
September 11, 2023 08:00 ET
|
Aquestive Therapeutics, Inc.
FDA Acceptance of Libervant™ (diazepam) Buccal Film NDA for treatment of seizure clusters in patients between two and five years of agePrescription Drug User Fee Act (PDUFA) target goal date set for...
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
August 23, 2023 08:00 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems...
Aquestive Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
August 07, 2023 16:01 ET
|
Aquestive Therapeutics, Inc.
Submitted proposed pivotal trial protocol for Anaphylm™ (epinephrine) Sublingual Film to the FDASubmitted an NDA to the FDA for Libervant™ (diazepam) Buccal Film for patients between two and five...
Aquestive Therapeutics to Participate in 2023 Wedbush PacGrow Healthcare Conference
August 02, 2023 08:00 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems...